CA
NZ
UK
AU
IND
US
…
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Doseology Sciences Inc (MOOD.CN) is limited and filings provide minimal operational detail. The company appears to be an early-stage life sciences issuer that may depend on R&D progress, intellectual property and strategic partnerships as long-term growth drivers. Some investors may find exposure to potential therapeutic or tech upside attractive, but that depends on execution of development milestones.
Material risks include limited disclosure and operating history, clinical and regulatory execution risk, need for external financing and low liquidity of a small-cap listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -0.45M | -0.34M | -1.78M | -1.94M | -1.63M |
| Net income | -0.45M | -0.34M | -1.78M | -1.94M | -1.63M |
| Selling general administrative | 0.43M | 0.35M | 0.68M | 1.00M | 0.69M |
| Gross profit | 0.02M | 0.07M | 0.04M | -0.15M | 0.00M |
| Reconciled depreciation | 0.00M | 0.02M | 0.07M | 0.14M | 0.09M |
| Operating income | -0.47M | -0.38M | -0.83M | -1.82M | -1.57M |
| Interest expense | - | 0.00M | 0.04M | 0.08M | 0.07M |
| Interest income | 0.02M | 0.03M | 0.07M | 0.01M | 0.00M |
| Net interest income | 0.02M | 0.03M | 0.03M | -0.07M | -0.07M |
| Total revenue | 0.04M | 0.10M | 0.04M | 0.02M | 0.00M |
| Total operating expenses | 0.51M | 0.48M | 0.88M | 1.83M | 1.57M |
| Cost of revenue | 0.02M | 0.03M | 0.00M | 0.16M | 0.00M |
| Total other income expense net | - | 0.01M | -0.98M | -0.05M | 0.01M |
| Net income from continuing ops | -0.45M | -0.34M | -1.78M | -1.94M | -1.63M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 1.49M | 1.10M | 1.40M | 3.87M | 5.99M |
| Intangible assets | - | - | - | 0.01M | 0.08M |
| Other current assets | - | - | - | - | -0.00M |
| Total liab | 0.09M | 0.08M | 0.10M | 0.87M | 3.41M |
| Total stockholder equity | 1.40M | 1.02M | 1.30M | 3.00M | 2.58M |
| Other current liab | - | - | - | - | 2.31M |
| Capital stock | 7.50M | 6.75M | 6.71M | 6.71M | 4.53M |
| Retained earnings | -6.57M | -6.12M | -5.78M | -4.00M | -2.06M |
| Cash | 1.43M | 1.06M | 1.30M | 1.87M | 3.73M |
| Total current liabilities | 0.09M | 0.08M | 0.09M | 0.22M | 2.75M |
| Total current assets | 1.49M | 1.10M | 1.34M | 2.97M | 5.00M |
| Net receivables | 0.02M | 0.00M | 0.00M | 0.01M | 0.00M |
| Inventory | 0.02M | 0.04M | 0.01M | 0.01M | 0.13M |
| Accounts payable | 0.04M | 0.05M | 0.02M | 0.09M | 0.06M |
| Non current assets total | 0.00M | 0.00M | 0.06M | 0.90M | 0.99M |
| Capital lease obligations | - | 0.00M | 0.05M | 0.75M | 0.69M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | - | - | 0.00M | 0.00M | -0.03M |
| Net borrowings | 0.00M | -0.01M | -0.09M | -0.12M | - |
| Total cash from financing activities | 0.71M | -0.01M | -0.09M | -0.14M | 5.79M |
| Net income | -0.45M | -0.34M | -1.78M | -1.94M | -1.63M |
| Change in cash | 0.37M | -0.24M | -0.57M | -1.86M | 3.39M |
| Begin period cash flow | 1.06M | 1.30M | 1.87M | 3.73M | 0.34M |
| End period cash flow | 1.43M | 1.06M | 1.30M | 1.87M | 3.73M |
| Total cash from operating activities | -0.34M | -0.24M | -0.48M | -1.71M | -2.37M |
| Issuance of capital stock | 0.73M | 0.00M | - | 0.00M | 3.84M |
| Depreciation | 0.00M | 0.02M | 0.07M | 0.14M | 0.09M |
| Change to inventory | 0.02M | -0.03M | 0.00M | -0.04M | -0.13M |
| Sale purchase of stock | - | - | - | 0.00M | -0.28M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.01M | 0.17M |
| Change in working capital | -0.01M | 0.03M | 0.14M | -0.28M | -0.92M |
| Stock based compensation | 0.10M | 0.02M | 0.08M | 0.09M | 0.02M |
| Other non cash items | 0.02M | 0.03M | 0.75M | 0.08M | 0.07M |
| Free cash flow | -0.34M | -0.24M | -0.48M | -1.72M | -2.54M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MOOD Doseology Sciences Inc |
0.01 17.65% |
0.10 | - | - | 50.45 | 3.77 | 53.50 | -1.30 |
| DRUG Bright Minds Biosciences Inc |
-0.11 0.42% |
26.00 | - | - | - | 13.50 | - | -0.10 |
| METX ME Therapeutics Holdings Inc. |
- -% |
1.05 | - | - | - | 72.00 | - | - |
| TELI Telescope Innovations Corp. |
-0.01 1.59% |
0.31 | - | - | 4.32 | 6.45 | 4.32 | -1.62 |
| DTC Defence Therapeutics Inc |
0.01 1.43% |
0.35 | - | - | - | 89.80 | - | -9.99 |
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.
| Name | Title | Year Born |
|---|---|---|
| Ms. Lindsay Hamelin | Corporate Secretary | NA |
| Mr. Christopher Jackson | CEO & Director | 1970 |
| Mr. Timothy Corkum | President & COO | 1973 |
| Mr. Daniel Vice | Co-Founder & Independent Director | NA |
| Mr. Christopher P. Cherry | Chief Financial Officer | NA |
| Mr. Lawrence Latowsky | Executive Chairman of the Board | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...